Navigation Links
Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results
Date:4/25/2008

HAYWARD, Calif., April 25 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) will announce its first quarter 2008 financial results on Thursday, May 1, 2008, after market close.

The announcement of Kosan's first quarter 2008 financial results will be followed by a conference call and live webcast on May 1, 2008 at 1:30 p.m. Pacific / 4:30 p.m. Eastern. Interested parties may access the live call by dialing 888.680.0878 (US) or 617.213.4855 (international), access code 63268386. To pre-register for the call, go to https://www.theconferencingservice.com/prereg/key.process?key=PLGLKCFUP or visit the "Investors/Press" page at http://www.kosan.com.

Interested parties may listen to the webcast live at http://www.kosan.com by clicking on the "Webcasts" tab under the heading, "Investors/Press."

The webcast is also being distributed over Thomson's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through Thomson's individual investor center at http://www.earnings.com or by visiting any of the investor sites in Thomson's Individual Investor Network. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents, at http://www.streetevents.com. A telephonic replay will be available through May 8, 2008 by dialing 888-286-8010, access code: 17626068. International callers can dial 617-801-6888, access code: 17626068.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- a Hsp90 (heat shock protein 90) inhibitor and an epothilone. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in a Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a Phase 1 trial. For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.


'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
2. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
3. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
4. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
5. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
6. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
7. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
8. Kosan Announces February 28, 2008 Conference Call and Webcast
9. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
10. Kosan Announces Third Quarter 2007 Financial Results
11. Kosan to Reacquire Epothilone Program From Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Diego, Calif. (PRWEB) , ... May 25, 2016 , ... ... Diego area and has consistently been rated one of its top attractions. Fortune ... the globe to participate in a unique and intimate team-building experience. , Each event ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... Michael Fitzmaurice recently became double board-certified in surgery and surgery of the hand ... Dr. Fitzmaurice is no stranger to going above and beyond in his pursuit ...
(Date:5/25/2016)... LAKE CITY, UTAH. (PRWEB) , ... May 25, 2016 , ... ... efficiencies in healthcare information exchange, today announced that Charles W. Stellar has been named ... as WEDI’s interim CEO since January 2016. As an executive leader with more than ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... attacks, diabetes, and traumatic injuries, will be accelerated by research at Worcester Polytechnic ... into engines of wound healing and tissue regeneration. , The novel method, developed ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
Breaking Biology News(10 mins):